$ADVM
Adverum Biotechnologies Inc

2019 Q1 Form 10-K Financial Statement

#000156459019006536 Filed on March 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018 Q3
Revenue $0.00 $70.00K $833.0K
YoY Change -100.0% -84.82% 79.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.580M $5.190M $4.830M
YoY Change 3.91% 28.47% 1.47%
% of Gross Profit
Research & Development $10.13M $11.64M $14.48M
YoY Change -20.81% -3.08% 40.99%
% of Gross Profit
Depreciation & Amortization $430.0K $390.0K $260.0K
YoY Change -6.52% -23.53% -50.94%
% of Gross Profit
Operating Expenses $15.71M $16.83M $24.31M
YoY Change -13.52% 4.81% 61.67%
Operating Profit -$15.71M
YoY Change -12.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.218M $1.100M $1.270M
YoY Change 63.27% 35.8% 71.16%
Pretax Income -$14.49M -$15.66M -$22.21M
YoY Change -15.76% 5.88% 60.59%
Income Tax $0.00 -$1.300M
% Of Pretax Income
Net Earnings -$14.49M -$15.66M -$20.96M
YoY Change -15.76% 5.88% 51.55%
Net Earnings / Revenue -22370.0% -2515.97%
Basic Earnings Per Share
Diluted Earnings Per Share -$229.5K -$248.8K -$335.6K
COMMON SHARES
Basic Shares Outstanding 63.20M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $189.5M $205.1M $217.9M
YoY Change -23.28% 7.66% 16.77%
Cash & Equivalents $145.1M $154.9M $159.7M
Short-Term Investments $45.40M $50.10M $58.20M
Other Short-Term Assets $3.600M $3.700M $4.300M
YoY Change 63.64% 12.12% 48.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $193.1M $208.8M $222.2M
YoY Change -22.51% 7.75% 17.26%
LONG-TERM ASSETS
Property, Plant & Equipment $26.70M $3.586M $2.600M
YoY Change 853.57% 18.58% -21.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.200M $156.0K $1.100M
YoY Change 1100.0% 11.43% 266.67%
Total Long-Term Assets $27.90M $4.741M $3.700M
YoY Change 248.75% -41.93% -57.47%
TOTAL ASSETS
Total Short-Term Assets $193.1M $208.8M $222.2M
Total Long-Term Assets $27.90M $4.741M $3.700M
Total Assets $221.0M $213.5M $225.9M
YoY Change -14.07% 5.74% 13.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $1.707M $1.700M
YoY Change 157.14% -1.39% 6.25%
Accrued Expenses $8.900M $8.800M $7.800M
YoY Change 23.61% 25.71% 27.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.60M $10.72M $10.10M
YoY Change 14.3% 0.18% 5.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $216.0K $243.0K $300.0K
YoY Change -46.53% -49.48% -95.31%
Total Long-Term Liabilities $216.0K $243.0K $300.0K
YoY Change -46.53% -49.48% -95.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.60M $10.72M $10.10M
Total Long-Term Liabilities $216.0K $243.0K $300.0K
Total Liabilities $32.90M $12.33M $10.40M
YoY Change 239.95% -31.04% -39.53%
SHAREHOLDERS EQUITY
Retained Earnings -$320.5M
YoY Change 26.17%
Common Stock $522.5M
YoY Change 19.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $188.1M $201.2M $215.6M
YoY Change
Total Liabilities & Shareholders Equity $221.0M $213.5M $225.9M
YoY Change -14.07% 5.74% 13.98%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$14.49M -$15.66M -$20.96M
YoY Change -15.76% 5.88% 51.55%
Depreciation, Depletion And Amortization $430.0K $390.0K $260.0K
YoY Change -6.52% -23.53% -50.94%
Cash From Operating Activities -$13.22M -$12.73M -$16.90M
YoY Change 1.79% 4.34% 69.34%
INVESTING ACTIVITIES
Capital Expenditures $2.186M -$160.0K -$270.0K
YoY Change 912.04% 60.0% 42.11%
Acquisitions
YoY Change
Other Investing Activities $4.930M $8.180M $21.41M
YoY Change -80.74% -76.49% 661.92%
Cash From Investing Activities $2.745M $8.020M $21.14M
YoY Change -89.19% -76.89% 706.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$370.0K -20.00K -20.00K
YoY Change -100.53% -100.12% -91.67%
NET CHANGE
Cash From Operating Activities -$13.22M -12.73M -16.90M
Cash From Investing Activities $2.745M 8.020M 21.14M
Cash From Financing Activities -$370.0K -20.00K -20.00K
Net Change In Cash -$10.84M -4.730M 4.220M
YoY Change -113.19% -112.08% -155.53%
FREE CASH FLOW
Cash From Operating Activities -$13.22M -$12.73M -$16.90M
Capital Expenditures $2.186M -$160.0K -$270.0K
Free Cash Flow -$15.40M -$12.57M -$16.63M
YoY Change 16.69% 3.88% 69.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63201009
CY2018Q2 dei Entity Public Float
EntityPublicFloat
294800000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154949000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70519000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
50130000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
119966000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3675000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3256000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
208754000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
193741000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3586000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3024000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
999000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
156000
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
243000
CY2018 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
168000
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-774000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57103000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8723000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
367000
CY2017 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4204000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5000000
CY2018Q4 us-gaap Assets
Assets
213495000
CY2017Q4 us-gaap Assets
Assets
201905000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1707000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1731000
CY2017Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6964000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
129000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1250000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1612000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1849000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-58847000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73877000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56147000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1250000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-72627000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
333000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72463000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.18
CY2017 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-182000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
215000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
487000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16519000
CY2017 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-25000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-953000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1016000
CY2018 advm Increase Decrease In Deposit And Other Noncurrent Assets
IncreaseDecreaseInDepositAndOtherNoncurrentAssets
16000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-67000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69444000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122204000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70187000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61375000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43661000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
215600000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16519000
CY2017 advm Adjustment To Additional Paid In Capital Remeasurement Of Contingent Common Stock Warrant
AdjustmentToAdditionalPaidInCapitalRemeasurementOfContingentCommonStockWarrant
60000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
175000
CY2017 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
313000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
70187000
CY2018 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
6146000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13432000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
688000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
340000
CY2018 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1191000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
230000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4140000
CY2018 us-gaap Profit Loss
ProfitLoss
-72627000
CY2017 us-gaap Profit Loss
ProfitLoss
-56147000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1750000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2096000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
13432000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
8723000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-24000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-593000
CY2018 us-gaap Accretion Expense
AccretionExpense
95000
CY2017 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
60000
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
17000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-10000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-886000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
793000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
491000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1849000
CY2018 us-gaap Straight Line Rent
StraightLineRent
-1243000
CY2017 us-gaap Straight Line Rent
StraightLineRent
97000
CY2018 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1250000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53964000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45421000
CY2018 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
78726000
CY2017 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
209787000
CY2017 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1003000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
148979000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
87596000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
809000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
688000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
367000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1191000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
313000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
340000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
175000
CY2018 us-gaap Repayments Of Debt
RepaymentsOfDebt
175000
CY2018 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
100000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69949000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16748000
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-774000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
85429000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-151651000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70519000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222170000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
155948000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1616000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
115000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, intangible asset, fair values of financial instruments and fair value of common stock warrants. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</font></p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Uncertainties<font style="font-weight:normal;">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support the growth.</p>
CY2018Q4 advm Cash Equivalents And Short Term Investments Unrealized Gains
CashEquivalentsAndShortTermInvestmentsUnrealizedGains
6000
CY2018Q4 advm Cash Equivalents And Short Term Investments Amortized Cost
CashEquivalentsAndShortTermInvestmentsAmortizedCost
202722000
CY2017Q4 advm Cash Equivalents And Short Term Investments Amortized Cost
CashEquivalentsAndShortTermInvestmentsAmortizedCost
177928000
CY2018 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
CY2018 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q4 advm Cash Equivalents And Short Term Investments Unrealized Gains
CashEquivalentsAndShortTermInvestmentsUnrealizedGains
1000
CY2018Q4 advm Cash Equivalents And Short Term Investments Unrealized Losses
CashEquivalentsAndShortTermInvestmentsUnrealizedLosses
21000
CY2017Q4 advm Cash Equivalents And Short Term Investments Unrealized Losses
CashEquivalentsAndShortTermInvestmentsUnrealizedLosses
183000
CY2018Q4 advm Cash Equivalents And Short Term Investments Fair Value
CashEquivalentsAndShortTermInvestmentsFairValue
202707000
CY2017Q4 advm Cash Equivalents And Short Term Investments Fair Value
CashEquivalentsAndShortTermInvestmentsFairValue
177746000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50145000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
120148000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
183000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50130000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
119966000
CY2018Q4 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0
CY2018 advm Investments Remaining Maturity Maximum Period
InvestmentsRemainingMaturityMaximumPeriod
P1Y
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
202722000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
177746000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10008000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7697000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6422000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4673000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2944000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2259000
CY2018Q4 advm Accrued Preclinical Costs Current
AccruedPreclinicalCostsCurrent
289000
CY2018Q4 advm Accrued Clinical And Development Process Costs Current
AccruedClinicalAndDevelopmentProcessCostsCurrent
1561000
CY2017Q4 advm Accrued Clinical And Development Process Costs Current
AccruedClinicalAndDevelopmentProcessCostsCurrent
910000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1699000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245000
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P4Y
CY2018 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-08
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3344000
CY2017Q4 advm Accrued Preclinical Costs Current
AccruedPreclinicalCostsCurrent
1255000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2291000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2295000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4221000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4683000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4846000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5016000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
28837000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
50947000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3300000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1800000
CY2018Q4 us-gaap Contractual Obligation
ContractualObligation
700000
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
500000
CY2018 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:MaintenanceMember
CY2017 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:MaintenanceMember
CY2018 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2017 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2018 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
CY2017 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
CY2018 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2017 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
1
CY2017Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
13000000
CY2018 advm Share Based Compensation Arrangement By Share Based Payment Award Options Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsClosingPriceOfCommonStockIntrinsicValueAmount
3.15
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8200000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4800000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.15
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.99
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6500000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13432000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8723000
CY2018 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
4100000
CY2018 advm Number Of Executives Departure
NumberOfExecutivesDeparture
2
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1300000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-45024000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-36923000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-28853000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-19224000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15514000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19090000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
19000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-1512000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-76000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
75000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
61000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
41000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1215000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
507000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
11219000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7935000
CY2018 advm Income Tax Reconciliation Change In Uncertain Tax Position
IncomeTaxReconciliationChangeInUncertainTaxPosition
6242000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37247000
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-586000
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1495000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
10163000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
216000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
493000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
833000
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70000
CY2018Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2745000
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2157000
CY2018 advm Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
1941000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
4119000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
588000
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
462000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8996000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9371000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27142000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
827000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2586000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4549000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3623000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4161000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1774000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
310000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
274000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
38000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
64000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
122000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47254000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35463000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47254000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35463000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1250000
CY2018 advm Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
0
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11800000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12000000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8805000
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
18162000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
20396000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
24306000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
16829000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-17200000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-18810000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-20958000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-15659000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
463000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
463000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
461000
CY2017Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2017Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2017Q4 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
17050000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
12556000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
15034000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
16056000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-16099000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-11430000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-13829000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-14789000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32

Files In Submission

Name View Source Status
0001564590-19-006536-index-headers.html Edgar Link pending
0001564590-19-006536-index.html Edgar Link pending
0001564590-19-006536.txt Edgar Link pending
0001564590-19-006536-xbrl.zip Edgar Link pending
advm-10k_20181231.htm Edgar Link pending
advm-20181231.xml Edgar Link completed
advm-20181231.xsd Edgar Link pending
advm-20181231_cal.xml Edgar Link unprocessable
advm-20181231_def.xml Edgar Link unprocessable
advm-20181231_lab.xml Edgar Link unprocessable
advm-20181231_pre.xml Edgar Link unprocessable
advm-ex1012_914.htm Edgar Link pending
advm-ex1016_910.htm Edgar Link pending
advm-ex1032_795.htm Edgar Link pending
advm-ex1034_794.htm Edgar Link pending
advm-ex1046_908.htm Edgar Link pending
advm-ex1047_912.htm Edgar Link pending
advm-ex1048_913.htm Edgar Link pending
advm-ex1049_847.htm Edgar Link pending
advm-ex231_8.htm Edgar Link pending
advm-ex232_846.htm Edgar Link pending
advm-ex311_17.htm Edgar Link pending
advm-ex312_10.htm Edgar Link pending
advm-ex321_13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4jaxyjomwtr000001.jpg Edgar Link pending
gbm3ee2ai0w5000001.jpg Edgar Link pending
gjzpgxddxm1g000001.jpg Edgar Link pending
gjzpgxddxm1g000002.jpg Edgar Link pending
gjzpgxddxm1g000003.jpg Edgar Link pending
gjzpgxddxm1g000004.jpg Edgar Link pending
gjzpgxddxm1g000005.jpg Edgar Link pending
gjzpgxddxm1g000006.jpg Edgar Link pending
gveivxsgdgol000001.jpg Edgar Link pending
gveivxsgdgol000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending